SG11202000625PA - Compositions in the form of an injectable aqueous solution comprising at least human insulin a21g and a prandial action glucagon suppressor - Google Patents

Compositions in the form of an injectable aqueous solution comprising at least human insulin a21g and a prandial action glucagon suppressor

Info

Publication number: SG11202000625PA
Authority: SG; Singapore
Prior art keywords: compositions; aqueous solution; human insulin; injectable aqueous; prandial action
Prior art date: 2017-07-27

Application number

SG11202000625PA

Inventor

You-Ping Chan

Original Assignee

Adocia

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-07-27

Filing date

2018-07-27

Publication date

2020-02-27

2017-07-27 Priority claimed from FR1757172A external-priority patent/FR3069436A1/en

2017-07-28 Priority claimed from FR1757184A external-priority patent/FR3069437A1/en

2018-06-14 Priority claimed from FR1855250A external-priority patent/FR3082426A1/en

2018-07-27 Application filed by Adocia filed Critical Adocia

2020-02-27 Publication of SG11202000625PA publication Critical patent/SG11202000625PA/en

Links

102000051325 Glucagon Human genes 0.000 title 1
108060003199 Glucagon Proteins 0.000 title 1
101000976075 Homo sapiens Insulin Proteins 0.000 title 1
239000007864 aqueous solution Substances 0.000 title 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
229960004666 glucagon Drugs 0.000 title 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Inorganic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Dermatology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Toxicology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

SG11202000625PA 2017-07-27 2018-07-27 Compositions in the form of an injectable aqueous solution comprising at least human insulin a21g and a prandial action glucagon suppressor SG11202000625PA (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
FR1757172A FR3069436A1 (en)	2017-07-27	2017-07-27	COMPOSITIONS IN THE FORM OF AN INJECTION AQUEOUS SOLUTION COMPRISING AT LEAST HUMAN INSULIN A21G AND A PRANDIAL-ACTING GLUCAGON SUPPRESSOR
FR1757184A FR3069437A1 (en)	2017-07-28	2017-07-28	COMPOSITIONS IN THE FORM OF AN INJECTION AQUEOUS SOLUTION COMPRISING AT LEAST HUMAN INSULIN A21G AND A PRANDIAL-ACTING GLUCAGON SUPPRESSOR
FR1855250A FR3082426A1 (en)	2018-06-14	2018-06-14	COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AT LEAST HUMAN INSULIN A21G AND A PRANDIAL ACTION GLUCAGON SUPPRESSOR
PCT/EP2018/070510 WO2019020820A2 (en)	2017-07-27	2018-07-27	Compositions in the form of an injectable aqueous solution comprising at least human insulin a21g and a prandial action glucagon suppressor

Publications (1)

Publication Number	Publication Date
SG11202000625PA true SG11202000625PA (en)	2020-02-27

Family

ID=63047385

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11202000625PA SG11202000625PA (en)	2017-07-27	2018-07-27	Compositions in the form of an injectable aqueous solution comprising at least human insulin a21g and a prandial action glucagon suppressor

Country Status (16)

Country	Link
US (2)	US10610572B2 (en)
EP (2)	EP3658115B1 (en)
JP (2)	JP7240004B2 (en)
KR (1)	KR20200034779A (en)
CN (1)	CN110996905A (en)
AU (2)	AU2018308692A1 (en)
BR (1)	BR112020001617A2 (en)
CA (1)	CA3071064A1 (en)
DK (1)	DK4019039T3 (en)
ES (2)	ES2969277T3 (en)
IL (1)	IL272141B2 (en)
MA (1)	MA49678A (en)
PH (1)	PH12020500122A1 (en)
PL (2)	PL4019039T3 (en)
SG (1)	SG11202000625PA (en)
WO (1)	WO2019020820A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201607918D0 (en)	2016-05-06	2016-06-22	Arecor Ltd	Novel formulations
SG11202000625PA (en) *	2017-07-27	2020-02-27	Adocia	Compositions in the form of an injectable aqueous solution comprising at least human insulin a21g and a prandial action glucagon suppressor
FR3082426A1 (en) *	2018-06-14	2019-12-20	Adocia	COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AT LEAST HUMAN INSULIN A21G AND A PRANDIAL ACTION GLUCAGON SUPPRESSOR
EP3915572A1 (en)	2020-05-29	2021-12-01	Adocia	Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action
EP3915571A1 (en)	2020-05-29	2021-12-01	Adocia	Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action
EP4144362A1 (en) *	2021-09-06	2023-03-08	Adocia	Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4129324A1 (en) *	2021-08-02	2023-02-08	Adocia	Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
EP4342486A1 (en)	2022-09-20	2024-03-27	Adocia	Compositions comprising at least an insulin and an amylin receptor agonist for treating diabetes, in a patient/person having a bmi of more than 28 kg/m² and/or an hba1c of more than 7.6 %

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5008241A (en)	1985-03-12	1991-04-16	Novo Nordisk A/S	Novel insulin peptides
CA1295330C (en)	1985-03-29	1992-02-04	James M. Greene	Synthesis of inotropic imidazo(4,5-c) pyridine
GB8720115D0 (en)	1987-08-26	1987-09-30	Cooper G J S	Treatment of diabetes mellitus
US5234906A (en)	1991-01-10	1993-08-10	Amylin Pharmaceuticals, Inc.	Hyperglycemic compositions
HU222249B1 (en)	1991-03-08	2003-05-28	Amylin Pharmaceuticals Inc.	Process for producing amyline antagonistic peptide derivatives and pharmaceutical preparatives containing them
BR9407424A (en)	1993-09-07	1996-04-09	Amylin Pharmaceuticals Inc	Methods to regulate gastrointestinal motility
US7312196B2 (en)	1997-01-08	2007-12-25	Amylin Pharmaceuticals, Inc.	Formulations for amylin agonist peptides
US6410511B2 (en)	1997-01-08	2002-06-25	Amylin Pharmaceuticals, Inc.	Formulations for amylin agonist peptides
US6506724B1 (en)	1999-06-01	2003-01-14	Amylin Pharmaceuticals, Inc.	Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
EP1076066A1 (en)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
EP2241327A1 (en)	2006-03-15	2010-10-20	Novo Nordisk A/S	Mixtures of Amylin and Insulin
WO2007135118A1 (en) *	2006-05-24	2007-11-29	Novo Nordisk A/S	Soluble, stable insulin-containing formulations
WO2008124522A2 (en)	2007-04-04	2008-10-16	Biodel, Inc.	Amylin formulations
WO2009004627A2 (en)	2007-07-02	2009-01-08	Medingo Ltd.	A device for drug delivery
EP2200635A1 (en)	2007-09-11	2010-06-30	Novo Nordisk A/S	Mixture comprising an amylin peptide and a protracted insulin
EP2060268A1 (en)	2007-11-15	2009-05-20	Novo Nordisk A/S	Pharmaceutical compositions for pulmonary or nasal delivery of peptides
AU2011202239C1 (en) *	2010-05-19	2017-03-16	Sanofi	Long-acting formulations of insulins
MX349383B (en)	2011-10-31	2017-07-26	Xeris Pharmaceuticals Inc	Formulations for the treatment of diabetes.
US20150174209A1 (en)	2012-05-25	2015-06-25	Amylin Pharmaceuticals. Llc	Insulin-pramlintide compositions and methods for making and using them
AU2014326181A1 (en) *	2013-09-30	2016-03-17	Wockhardt Limited	Pharmaceutical composition
HUE062573T2 (en)	2014-12-12	2023-11-28	Sanofi Aventis Deutschland	Insulin glargine/lixisenatide fixed ratio formulation
SG11202000625PA (en) *	2017-07-27	2020-02-27	Adocia	Compositions in the form of an injectable aqueous solution comprising at least human insulin a21g and a prandial action glucagon suppressor

2018
- 2018-07-27 SG SG11202000625PA patent/SG11202000625PA/en unknown
- 2018-07-27 EP EP18746942.4A patent/EP3658115B1/en active Active
- 2018-07-27 CA CA3071064A patent/CA3071064A1/en active Pending
- 2018-07-27 US US16/048,007 patent/US10610572B2/en active Active
- 2018-07-27 PL PL22156880.1T patent/PL4019039T3/en unknown
- 2018-07-27 ES ES22156880T patent/ES2969277T3/en active Active
- 2018-07-27 BR BR112020001617-9A patent/BR112020001617A2/en unknown
- 2018-07-27 CN CN201880050233.9A patent/CN110996905A/en active Pending
- 2018-07-27 EP EP22156880.1A patent/EP4019039B1/en active Active
- 2018-07-27 KR KR1020207005615A patent/KR20200034779A/en active IP Right Grant
- 2018-07-27 DK DK22156880.1T patent/DK4019039T3/en active
- 2018-07-27 MA MA049678A patent/MA49678A/en unknown
- 2018-07-27 AU AU2018308692A patent/AU2018308692A1/en not_active Abandoned
- 2018-07-27 PL PL18746942.4T patent/PL3658115T4/en unknown
- 2018-07-27 IL IL272141A patent/IL272141B2/en unknown
- 2018-07-27 WO PCT/EP2018/070510 patent/WO2019020820A2/en unknown
- 2018-07-27 JP JP2020503975A patent/JP7240004B2/en active Active
- 2018-07-27 ES ES18746942T patent/ES2917893T3/en active Active
2020
- 2020-01-17 PH PH12020500122A patent/PH12020500122A1/en unknown
- 2020-02-25 US US16/800,658 patent/US11065305B2/en active Active
2023
- 2023-02-22 JP JP2023026282A patent/JP2023078143A/en active Pending
- 2023-05-05 AU AU2023202831A patent/AU2023202831A1/en active Pending

Also Published As

Publication number	Publication date
PL3658115T3 (en)	2022-08-08
PL4019039T3 (en)	2024-03-18
US20190054149A1 (en)	2019-02-21
DK4019039T3 (en)	2024-01-15
EP4019039A1 (en)	2022-06-29
ES2917893T3 (en)	2022-07-12
KR20200034779A (en)	2020-03-31
JP2020528439A (en)	2020-09-24
CA3071064A1 (en)	2019-01-31
EP3658115A2 (en)	2020-06-03
US11065305B2 (en)	2021-07-20
CN110996905A (en)	2020-04-10
AU2018308692A1 (en)	2020-03-05
IL272141B2 (en)	2024-07-01
AU2023202831A1 (en)	2023-05-25
IL272141B1 (en)	2024-03-01
EP4019039B1 (en)	2023-10-11
IL272141A (en)	2020-03-31
WO2019020820A2 (en)	2019-01-31
JP2023078143A (en)	2023-06-06
PH12020500122A1 (en)	2020-09-14
EP3658115B1 (en)	2022-02-23
PL3658115T4 (en)	2022-08-08
WO2019020820A3 (en)	2019-03-28
MA49678A (en)	2021-04-14
BR112020001617A2 (en)	2020-07-21
JP7240004B2 (en)	2023-03-15
US20200188487A1 (en)	2020-06-18
US10610572B2 (en)	2020-04-07
ES2969277T3 (en)	2024-05-17

Publication	Publication Date	Title
IL272141A (en)	2020-03-31	Compositions in the form of an injectable aqueous solution comprising at least human insulin a21g and a prandial action glucagon suppressor
IL291291A (en)	2022-05-01	Glucagon derivative and a composition comprising a long acting conjugate of the same
IL275184A (en)	2020-07-30	Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
SG11201604710XA (en)	2016-07-28	Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
SG11201604708VA (en)	2016-07-28	Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
IL246483A0 (en)	2016-08-31	Stable glucagon analogues and use for treatment of hypoglycaemia
IL266279B1 (en)	2023-03-01	Stable aqueous capsaicin injectable formuatlions and medical uses thereof
SG11202004786QA (en)	2020-07-29	Dried implant composition and injectable aqueous implant formulation
ZA201907833B (en)	2022-06-29	Heteroarylphenylaminoquinolines and analogues
IL275146A (en)	2020-07-30	Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
IL253600A0 (en)	2017-09-28	Insulin analogues and compositions comprising same
HUE042546T2 (en)	2019-07-29	Syringe with track-indexed plunger rod
IL241357B (en)	2021-08-31	Site 2 insulin analogues and uses thereof
SG11202005320VA (en)	2020-07-29	Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
SG11202005319PA (en)	2020-07-29	Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
EP3409292A4 (en)	2019-10-16	Stabilized aqueous composition comprising chondroitin sulfate and hyaluronic acid
GB201616398D0 (en)	2016-11-09	Syringe plunger rod
PL4073097T3 (en)	2024-10-28	Novel insulin analogues and uses thereof
IL272394A (en)	2020-03-31	Novel acylated insulin analogues and uses thereof
EP3883618C0 (en)	2023-08-02	Injectable composition including hyaluronic acid and use of said composition
PL3297626T3 (en)	2021-12-13	Ophthalmic composition comprising lipoic acid and hyaluronic acid
IL273967A (en)	2020-05-31	Aqueous compositions comprising bilastine and mometasone
IL262573A (en)	2018-12-31	Ophthalmic composition comprising a synergistic combination of glycogen and hyaluronic acid or a salt thereof
GB201401706D0 (en)	2014-03-19	Nanoparticle-insulin and insulin analogue compositions
SG10201913433SA (en)	2020-03-30	Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives